Velpatasvir-Sofosbuvir

Sofosbuvir/Velpatasvir is a fixed dose combination medication for the treatment of hepatitis C. It combines Sofosbuvir 400mg and Velpatasvir 100mg. It is more than 90% effective for hepatitis C genotypes one through six

Sofosbuvir-Velpatasvir is the first available Pangenotypic NS5A-NS5B inhibitor single-pill combination regimen, and is highly efficacious across HCV genotypes 1 to 6. It provides a much-needed interferon-free option for patients with genotype 3 infection that is more economical than Sofosbuvir plus Daclatasvir, and in patients who have compensated cirrhosis with genotype 3, this single-pill option provides an important Ribavirin-free combination.